Bharat Parenterals
1,047.00
+2.00(+0.19%)
Market Cap₹721.58 Cr
PE Ratio-25.20
IndustryHealthcare
Company Performance:
1D+0.19%
1M-8.36%
6M-16.30%
1Y+3.92%
5Y+201.73%
View Company Insightsright
More news about Bharat Parenterals
28Jul 25
Bharat Parenterals Reports Q1FY26 Results, Announces Board Changes and AGM Date
Bharat Parenterals Limited (BPL) reported its Q1 FY26 results. Standalone revenue increased by 2.50% to ₹94.37 crore, while consolidated revenue grew 25.40% to ₹116.00 crore. The company narrowed its consolidated net loss to ₹0.87 crore. BPL projects standalone revenue growth of 12-14% for FY26 with an EBITDA margin of 15-17%. Board changes include Mr. Sanjay Shah's resignation and Mr. Alkesh Jayantilal Shah's appointment as Additional Non-Executive Non-Independent Director. The 32nd AGM is scheduled for September 26, 2025.
 no imag found
12May 25
Bharat Parenterals Q4 FY23: EBITDA Surges Despite Widening Net Loss
Bharat Parenterals Ltd. (BPL) released Q4 FY23 results showing strong operational growth but increased net loss. Revenue rose 47.49% YoY to ₹100.00 crore, EBITDA doubled to ₹22.00 crore with margin improving to 2.14%. However, net loss widened to ₹4.70 crore from ₹0.30 crore in Q4 FY22.
 no imag found
Bharat Parenterals
1,047.00
+2.00
(+0.19%)
1 Year Returns:+3.92%
Industry Peers
Sun Pharmaceutical
1,693.60
(-2.02%)
Divis Laboratories
5,856.50
(-0.85%)
Torrent Pharmaceuticals
3,987.20
(-3.02%)
Lupin
2,274.50
(-0.02%)
Dr Reddys Laboratories
1,217.30
(+0.64%)
Cipla
1,192.40
(-0.29%)
Zydus Life Science
864.25
(+0.12%)
Mankind Pharma
1,998.50
(-0.14%)
Aurobindo Pharma
1,333.70
(-0.63%)
Alkem Laboratories
5,258.00
(+0.26%)